
    
      MC-1101 is a topical version of a previously approved anti-hypertensive drug that is intended
      to increase choroidal blood flow.

        -  A reduction of choroidal blood flow has been identified in patients with AMD

        -  This study will evaluate 0.5% and 1.0% potencies of MC-1101 delivered 2X per day.
    
  